Unlock instant, AI-driven research and patent intelligence for your innovation.

Albumin binding antibodies and use thereof

An albumin-binding, anti-albumin technology, applied in the field of albumin-binding antibodies and their uses, can solve the problems of increased medical system costs and decreased patient compliance.

Pending Publication Date: 2021-10-15
安维达生物科技公司
View PDF56 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

All of these factors lead to decreased patient adherence and increased costs to the healthcare system

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Albumin binding antibodies and use thereof
  • Albumin binding antibodies and use thereof
  • Albumin binding antibodies and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0500] Example 1. Production of anti-HSA single domain antibodies

[0501] Human serum albumin (HSA) expressed in mice (Sigma, #A9731) was used to immunize llamas to produce anti-HSA single domain antibodies (V H H antibody). After immunization, peripheral mononuclear cells (PBMCs) were isolated for RNA extraction. Use mRNA / cDNA encoding antibody genes to construct V H H Antibody Phage Display Library. The constructed phage display library was screened by multiple rounds of affinity binding to the antigen. pass Affinity measurement ( RED96) to identify positive clones. Sequence the antibody genes of positive clones and clone these genes into Vector (EMD Millipore, #CS221284) for expression in Chinese hamster ovary (CHO) cells.

[0502] Table 4 lists exemplary anti-HSA single domains (e.g. V H H) Antibodies (eg antibodies A1 to A18). These exemplary V H The CDR sequences of the H antibody are listed in Table 5. Among these antibodies, antibody A8 interacts with h...

Embodiment 2

[0509] Example 2. Production of Humanized Anti-HSA Single Domain Antibodies

[0510] Each llama sequence of the anti-HSA single domain antibody (sdAb) was directed against Databases were compared to identify the best matching human IGHV3 germline. When multiple germlines have similar homology, use The similarity of the amino acid at position 52 of FR2 in the numbering system was used to determine which germline to use as the humanized scaffold. FR1 and FR3 from the selected germline were then used as "humanized" FR1 and FR3. For FR2, most of the human sequences were adopted except for positions 42 and 52, where the respective llama sequences were retained. Table 6 shows exemplary human FR region sequences for each of the anti-HSA antibodies. For human FR4, the humanized antibodies A1-A9, A19 and A20 each independently have the amino acid sequence of WGQGTQVTVSS (SEQ ID NO: 145), WGQGTLVTVSS (SEQ ID NO: 146) or SGQGTQVTVSS (SEQ ID NO: 147). In one embodiment, humanized a...

Embodiment 3

[0514] Example 3. Binding-dissociation constants (K for anti-albumin antibodies D )

[0515] Evaluation V H The ability of H anti-albumin antibody to interact with human, monkey and mouse serum albumin at different pH values ​​(eg, pH 7.4 or pH 5.5) to mimic the pH of acidifying endosomes. In short, put V H H anti-albumin antibody fused to human IgG1-Fc. The expressed protein was then loaded onto the Protein A biosensor ( RED96). The biosensor is then immersed in a solution containing human, monkey or mouse serum at three or more different concentrations, for example 50 nM, 100 nM or 200 nM, or 100 nM, 200 nM or 400 nM. The main experimental data were analyzed with an overall fit to determine the binding-dissociation constant (K D ). The results are summarized in Table 7 (pH 5.5) and Table 8 (pH 7.4), where A represents a value not greater than 10 nM, B represents a value greater than 10 nM but not greater than 100 nM, and C represents a value greater than 100 nM but n...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides anti-albumin constructs each comprising an antialbumin single-domain antibody (sdAb) moiety. The anti-albumin constructs can further comprise a therapeutic agent, such as an antigen binding moiety or a cytokine. The present disclosure also provides methods of making and using the anti-albumin constructs.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to U.S. Provisional Application No. 62 / 809,475, filed February 22, 2019, the disclosure of which is incorporated herein by reference in its entirety. technical field [0003] The present disclosure relates to anti-albumin constructs comprising an anti-albumin single domain antibody (sdAb) portion and methods of making and using the same. [0004] Sequence Listing Reference [0005] This specification is filed together with a sequence listing in computer readable form (CRF) of size 117,812 bytes created on February 21, 2020, entitled 216A003WO01_SEQLIST_ST25.txt, the contents of which are hereby incorporated by reference in their entirety. Background technique [0006] Many therapeutic agents, especially biologics such as peptides, polypeptides and polynucleotides, have limited utility due to their short serum half-lives. Due to short serum half-lives, some therapeutic a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/18A61K39/395C07K14/76
CPCC07K14/76C07K16/18C07K2317/569C07K2317/22C07K2317/24C07K2317/92C07K2319/00A61P35/00
Inventor 钟子洋叶帆马修.西格黄嘉宁埃里克·寥伊娜·李
Owner 安维达生物科技公司